The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Advances in liposomal drug delivery to cancer: An overview
Abstract
Abstract Liposomes are biodegradable and biocompatible lipid bilayer vesicles which are widely exploited as preferred carriers for smart delivery of both hydrophobic as well as hydrophilic bioactives. Structural fabrication of liposomes for ligand anchoring, long-circulation and stimuli-responsiveness are advancing features to meet the needs of clinical and industrial demands. Recent studies report newer developments in multipronged liposomes for synchronized theranostic manifestations in cancer treatment. This review gives an insight to advances in ligand targeted liposomes (like folate, mannose, transferrin, hyaluronic acid, antibody, aptamer, and peptide, etc.), stimuli-triggered liposomes (stimuli such as pH, temperature, and hypoxia, etc.) and liposomes mediated autophagy modulation, and theranostic liposomes for the diagnosis and treatment of cancer. It also includes patents, clinical studies and marketed liposomal products. This assemblage of advances would be of great interest to budding scientists and pharmaceutical companies engaged in the development of liposomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
Pancreatic cancers require autophagy for tumor growth
Yang, S., Wang, X., Contino, G., Liesa, M., Sahin, E., Ying, H., Bause, A., Li, Y., Stommel, J. M., Dell'Antonio, G., et al. (2011) · Genes & Development · doi:10.1101/gad.2016111 · Cited by 1,498
Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis
Guo, J. Y., Chen, H.-Y., Mathew, R., Fan, J., Strohecker, A. M., Karsli-Uzunbas, G., Kamphorst, J. J., Chen, G., Lemons, J. M. S., Karantza, V., et al. (2011) · Genes & Development · doi:10.1101/gad.2016311 · Cited by 1,323
Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation
Jones, A. R., & Shusta, E. V. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9379-0 · Cited by 549
Liposomes for scintigraphic detection of infection and inflammation
Laverman, P. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00095-7 · Cited by 93
Cited by
Liu, P., Chen, G., & Zhang, J. (2022) · Molecules · doi:10.3390/molecules27041372 · Cited by 1,334
“The high molecular weight of PEG (>2000 Da) grafted to the lipid headgroup exhibits repulsive forces from the liposome surface, as well as protects liposomes from binding serum proteins and avoids further clearance by the mononuclear phagocytic system (MPS), but also decreases the interaction and endocytosis of liposo…”
BackgroundDesign of liposomes as drug delivery system for therapeutic applications
Guimarães, D., Cavaco-Paulo, A., & Nogueira, E. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120571 · Cited by 1,196
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 521
Nanoparticles in cancer theragnostic and drug delivery: A comprehensive review
Al-Thani, A. N., Jan, A. G., Abbas, M., Geetha, M., & Sadasivuni, K. K. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122899 · Cited by 323
Metadata
- Authors
- Saraf, S., Jain, A., Tiwari, A., Verma, A., Panda, P. K., & Jain, S. K.
- Venue
- Journal of Drug Delivery Science and Technology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 56
- Pages
- 101549
- ISSN
- 1773-2247 (ISSN-L)
- OpenAlex
- W3001177047
- Cited by
- 237
- References
- 6
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.